Courier Capital LLC Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Courier Capital LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 47.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 63,974 shares of the biopharmaceutical company’s stock after selling 58,150 shares during the period. Courier Capital LLC’s holdings in Pfizer were worth $1,775,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of PFE. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. Creekmur Asset Management LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $32,000. VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer in the fourth quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in shares of Pfizer in the fourth quarter worth about $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.4 %

Pfizer stock traded up $0.38 during trading hours on Thursday, hitting $27.80. 27,944,899 shares of the stock traded hands, compared to its average volume of 40,970,031. The firm’s 50-day moving average price is $27.81 and its two-hundred day moving average price is $27.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The company has a market cap of $157.53 billion, a PE ratio of -458.26, a PEG ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the firm posted $1.23 EPS. The business’s revenue was down 19.5% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.